Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhongmei Healthcare Plans $150 Million IPO in Hong Kong

publication date: Mar 31, 2016
Zhongmei Healthcare, a group of private China hospitals, plans to stage a $150 million IPO in Hong Kong during Q2. In January, the Carlyle Group acquired a 15.7% stake in Zhongmei for a $64 million investment, implying a valuation of $408 million. Zhongmei, which will offer 25% of its shares in the IPO, owns three renal care hospitals, one aesthetic surgical hospital and two general hospitals. The company will allocate 30% of the proceeds toward further acquisitions. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital